553 | Humans |
303 | Germany |
295 | Germany (epidemiology) |
254 | Female |
249 | Male |
220 | Influenza, Human (epidemiology) |
213 | Influenza, Human (prevention & control) |
211 | Adult |
202 | Middle Aged |
165 | Aged |
158 | Adolescent |
151 | Child |
124 | Child, Preschool |
122 | Influenza Vaccines (administration & dosage) |
118 | Animals |
113 | Young Adult |
108 | Infant |
80 | Risk Factors |
76 | Influenza, Human (virology) |
75 | Aged, 80 and over |
74 | Seasons |
57 | Incidence |
55 | Influenza, Human (diagnosis) |
54 | Vaccination (statistics & numerical data) |
51 | Prevalence |
51 | Infant, Newborn |
48 | Influenza Vaccines (immunology) |
47 | Influenza, Human (immunology) |
47 | Influenza A Virus, H1N1 Subtype |
45 | Surveys and Questionnaires |
41 | Influenza, Human (transmission) |
41 | Influenza in Birds (epidemiology) |
40 | Influenza, Human (mortality) |
40 | Cross-Sectional Studies |
39 | Disease Outbreaks (prevention & control) |
39 | Antibodies, Viral (blood) |
39 | Age Factors |
37 | Influenza Vaccines (therapeutic use) |
37 | Disease Outbreaks |
35 | Influenza A virus (isolation & purification) |
33 | Influenza Vaccines (adverse effects) |
32 | Phylogeny |
32 | Influenza A Virus, H1N1 Subtype (isolation & purification) |
32 | Influenza A Virus, H1N1 Subtype (immunology) |
31 | Population Surveillance |
31 | Influenza in Birds (virology) |
31 | Disease Outbreaks (statistics & numerical data) |
31 | Antiviral Agents (therapeutic use) |
30 | Pandemics |
29 | Treatment Outcome |
29 | Risk Assessment |
29 | Respiratory Tract Infections (epidemiology) |
29 | Orthomyxoviridae Infections (veterinary) |
29 | Berlin |
29 | Age Distribution |
27 | Influenza, Human (drug therapy) |
26 | Vaccination |
26 | Population Surveillance (methods) |
25 | Retrospective Studies |
25 | Prospective Studies |
25 | Health Knowledge, Attitudes, Practice |
24 | Time Factors |
24 | Practice Guidelines as Topic |
24 | Orthomyxoviridae Infections (epidemiology) |
24 | Disease Outbreaks (veterinary) |
23 | Swine |
22 | Influenza A virus (genetics) |
21 | Influenza Vaccines |
21 | Attitude of Health Personnel |
20 | Seroepidemiologic Studies |
20 | Respiratory Tract Infections (virology) |
20 | Pregnancy |
20 | Mass Vaccination (statistics & numerical data) |
20 | Influenza, Human (complications) |
20 | Influenza A virus (immunology) |
20 | Influenza A virus (classification) |
20 | Hemagglutination Inhibition Tests |
20 | Birds |
19 | Swine Diseases (virology) |
19 | Pandemics (prevention & control) |
19 | Health Surveys |
19 | Case-Control Studies |
18 | Orthomyxoviridae Infections (virology) |
18 | Influenza, Human (therapy) |
18 | Influenza A Virus, H1N1 Subtype (genetics) |
17 | Sensitivity and Specificity |
17 | Risk Assessment (methods) |
17 | Hospitalization (statistics & numerical data) |
17 | Cross Infection (prevention & control) |
16 | Sex Distribution |
16 | Sentinel Surveillance |
16 | Pandemics (statistics & numerical data) |
16 | Cross Infection (epidemiology) |
15 | Influenza in Birds (transmission) |
15 | Acute Disease |
14 | Swine Diseases (epidemiology) |
14 | Immunization Schedule |
14 | Comorbidity |
14 | Cause of Death |
13 | Respiratory Tract Infections (diagnosis) |
13 | Molecular Sequence Data |
13 | Influenza, Human (economics) |
13 | Influenza A Virus, H5N1 Subtype (isolation & purification) |
13 | Hemagglutinin Glycoproteins, Influenza Virus (genetics) |
13 | Cohort Studies |
12 | Vaccination (standards) |
12 | Vaccination (methods) |
12 | Travel |
12 | Reverse Transcriptase Polymerase Chain Reaction |
12 | Pneumococcal Vaccines (administration & dosage) |
12 | Patient Acceptance of Health Care (statistics & numerical data) |
12 | Neuraminidase (genetics) |
12 | Neuraminidase (antagonists & inhibitors) |
12 | Influenza, Human (history) |
12 | Influenza B virus (isolation & purification) |
12 | Influenza A Virus, H3N2 Subtype (isolation & purification) |
12 | Influenza A Virus, H1N1 Subtype (pathogenicity) |
12 | History, 20th Century |
12 | Anti-Bacterial Agents (therapeutic use) |
11 | Viruses (isolation & purification) |
11 | Virus Diseases (epidemiology) |
11 | Vaccination (psychology) |
11 | Oseltamivir (therapeutic use) |
11 | Models, Statistical |
11 | Logistic Models |
11 | Influenza, Human (nursing) |
11 | Influenza Vaccines (supply & distribution) |
11 | Influenza A Virus, H3N2 Subtype (immunology) |
11 | Genetic Variation |
11 | Cost-Benefit Analysis |
10 | Vaccination (adverse effects) |
10 | Survival Rate |
10 | Survival Analysis |
10 | Respiratory Syncytial Virus Infections (epidemiology) |
10 | Pneumococcal Vaccines |
10 | Pneumococcal Infections (prevention & control) |
10 | Netherlands (epidemiology) |
10 | Influenza, Human |
10 | Influenza, Human (pathology) |
10 | Influenza Vaccines (economics) |
10 | Influenza B virus (immunology) |
10 | Influenza A virus |
10 | Influenza A virus (pathogenicity) |
10 | Influenza A Virus, H3N2 Subtype (genetics) |
10 | Hospitals, University |
10 | Cost of Illness |
10 | Communicable Diseases (epidemiology) |
10 | Animals, Wild |
9 | World Health Organization |
9 | Reassortant Viruses (genetics) |
9 | Models, Theoretical |
9 | Immunization, Secondary |
9 | Immunization Programs (statistics & numerical data) |
9 | Hospitalization |
9 | Health Personnel |
9 | Forecasting |
9 | Europe |
9 | Diagnosis, Differential |
9 | Communicable Disease Control (organization & administration) |
8 | Vaccination (trends) |
8 | Switzerland (epidemiology) |
8 | Sequence Analysis, DNA |
8 | Risk |
8 | Reproducibility of Results |
8 | Poultry |
8 | Patient Education as Topic |
8 | Orthomyxoviridae (immunology) |
8 | Occupational Diseases (prevention & control) |
8 | Nasopharynx (virology) |
8 | Medical Staff, Hospital (statistics & numerical data) |
8 | Interviews as Topic |
8 | Influenza in Birds (pathology) |
8 | Influenza Vaccines (standards) |
8 | Influenza A Virus, H5N1 Subtype (genetics) |
8 | Influenza A Virus, H1N1 Subtype (classification) |
8 | Immunization Programs |
8 | Germany, West |
8 | Family Characteristics |
8 | Epidemics |
8 | Cross Infection (transmission) |
8 | Chickens |
8 | Birds (virology) |
8 | Base Sequence |
8 | Antiviral Agents (pharmacology) |
8 | Animals, Wild (virology) |
7 | Virus Diseases (virology) |
7 | Virus Diseases (diagnosis) |
7 | Virulence |
7 | Vaccination (legislation & jurisprudence) |
7 | United States |
7 | United States (epidemiology) |
7 | Sex Factors |
7 | Reverse Transcriptase Polymerase Chain Reaction (methods) |
7 | RNA, Viral (genetics) |
7 | Polymerase Chain Reaction |
7 | Paramyxoviridae Infections (epidemiology) |
7 | Orthomyxoviridae |
7 | Orthomyxoviridae (isolation & purification) |
7 | Italy (epidemiology) |
7 | Internet |
7 | Influenza, Human (psychology) |
7 | Influenza, Human (blood) |
7 | Influenza A Virus, H5N1 Subtype (pathogenicity) |
7 | Infectious Disease Transmission, Professional-to-Patient (prevention & control) |
7 | Germany, East |
7 | Dogs |
7 | Computer Simulation |
7 | Community-Acquired Infections (epidemiology) |
7 | Communicable Diseases, Emerging (epidemiology) |
7 | Communicable Disease Control (methods) |
7 | Cats |
7 | Berlin (epidemiology) |
7 | Antigens, Viral (immunology) |
7 | Amino Acid Sequence |
6 | Virology (methods) |
6 | Viral Vaccines (administration & dosage) |
6 | Utilization Review |
6 | Species Specificity |
6 | Severity of Illness Index |
6 | Respiratory Syncytial Virus Infections (virology) |
6 | RNA, Viral (analysis) |
6 | Public Health |
6 | Orthomyxoviridae Infections (immunology) |
6 | Orthomyxoviridae (classification) |
6 | Mass Vaccination (standards) |
6 | Mass Vaccination (methods) |
6 | Influenza, Human (physiopathology) |
6 | Influenza in Birds (prevention & control) |
6 | Influenza A Virus, H5N1 Subtype |
6 | Hygiene |
6 | Health Care Surveys |
6 | Guideline Adherence |
6 | France (epidemiology) |
6 | Follow-Up Studies |
6 | European Union |
6 | Drug Resistance, Viral |
6 | Data Collection |
6 | Cross Infection (mortality) |
6 | Cluster Analysis |
6 | Chick Embryo |
6 | Austria (epidemiology) |
6 | Antibody Formation (immunology) |
6 | Absenteeism |
5 | Zoonoses |
5 | Whooping Cough (prevention & control) |
5 | Vaccination (economics) |
5 | United Kingdom (epidemiology) |
5 | Telephone |
5 | Real-Time Polymerase Chain Reaction |
5 | Quality-Adjusted Life Years |
5 | Prognosis |
5 | Primary Health Care |
5 | Poultry Diseases (virology) |
5 | Poultry Diseases (epidemiology) |
5 | Poultry (virology) |
5 | Polymerase Chain Reaction (methods) |
5 | Pneumonia, Viral (mortality) |
5 | Pneumonia, Viral (diagnosis) |
5 | Pneumococcal Infections (epidemiology) |
5 | Pilot Projects |
5 | Pharynx (virology) |
5 | Patient Compliance (statistics & numerical data) |
5 | Patient Acceptance of Health Care |
5 | Pandemics (history) |
5 | Oseltamivir (pharmacology) |
5 | Odds Ratio |
5 | Occupational Diseases (epidemiology) |
5 | National Health Programs |
5 | Multiplex Polymerase Chain Reaction |
5 | Mortality (trends) |
5 | Models, Biological |
5 | Mass Vaccination |
5 | Mass Vaccination (trends) |
5 | Mass Vaccination (organization & administration) |
5 | Influenza, Human (etiology) |
5 | Influenza B virus (genetics) |
5 | Influenza A virus (drug effects) |
5 | Influenza A Virus, H3N2 Subtype |
5 | Influenza A Virus, H3N2 Subtype (drug effects) |
5 | Influenza A Virus, H3N2 Subtype (classification) |
5 | Influenza A Virus, H1N1 Subtype (physiology) |
5 | Influenza A Virus, H1N1 Subtype (drug effects) |
5 | Hospitals |
5 | Horses |
5 | Health Status |
5 | Health Promotion (statistics & numerical data) |
5 | Health Personnel (statistics & numerical data) |
5 | Guideline Adherence (statistics & numerical data) |
5 | Genotype |
5 | Family Health |
5 | Ducks (virology) |
5 | Disease Outbreaks (history) |
5 | Disaster Planning (organization & administration) |
5 | Databases, Factual |
5 | Cross Infection (virology) |
5 | Community-Acquired Infections (diagnosis) |
5 | Communicable Disease Control (statistics & numerical data) |
5 | Cloaca (virology) |
5 | Cell Line |
5 | Cat Diseases (epidemiology) |
5 | Bird Diseases (virology) |
5 | Bird Diseases (epidemiology) |
5 | Belgium (epidemiology) |
5 | Austria |
5 | Antiviral Agents (administration & dosage) |
5 | Amino Acid Substitution |
5 | Adjuvants, Immunologic (adverse effects) |
5 | Adjuvants, Immunologic (administration & dosage) |
4 | Zanamivir (pharmacology) |
4 | Viruses (genetics) |
4 | Virus Shedding |
4 | Vaccines, Inactivated (immunology) |
4 | Vaccines, Combined (administration & dosage) |
4 | Vaccines, Attenuated (administration & dosage) |
4 | Vaccines (administration & dosage) |
4 | Turkeys (virology) |
4 | Trachea (virology) |
4 | Tetanus Toxoid (administration & dosage) |
4 | Temperature |
4 | Swine (virology) |
4 | Serologic Tests |
4 | Sequence Alignment |
4 | Sentinel Surveillance (veterinary) |
4 | Safety |
4 | Risk Management (methods) |
4 | Reverse Transcriptase Polymerase Chain Reaction (veterinary) |
4 | Respiratory Tract Diseases (epidemiology) |
4 | Registries |
4 | Public Opinion |
4 | Primary Health Care (statistics & numerical data) |
4 | Practice Patterns, Physicians' |
4 | Poultry Diseases (prevention & control) |
4 | Portugal (epidemiology) |
4 | Population Density |
4 | Polymerase Chain Reaction (veterinary) |
4 | Pneumonia, Pneumococcal (prevention & control) |
4 | Pneumonia (epidemiology) |
4 | Physician's Role |
4 | Particle Size |
4 | Netherlands |
4 | Mutation |
4 | Microbial Sensitivity Tests |
4 | Internationality |
4 | Influenza, Human (classification) |
4 | Influenza in Birds (diagnosis) |
4 | Influenza A Virus, H5N1 Subtype (classification) |
4 | Influenza A Virus, H1N2 Subtype (isolation & purification) |
4 | Infectious Disease Transmission, Patient-to-Professional (prevention & control) |
4 | Immunoglobulin G (blood) |
4 | Horse Diseases (epidemiology) |
4 | Hemagglutination Inhibition Tests (veterinary) |
4 | Health Promotion (methods) |
4 | Health Policy |
4 | Health Behavior |
4 | Haemophilus Vaccines (administration & dosage) |
4 | Global Health |
4 | Genome, Viral |
4 | Genes, Viral |
4 | General Practice |
4 | France |
4 | Feces (virology) |
4 | Evidence-Based Medicine |
4 | Epidemiological Monitoring |
4 | Enzyme-Linked Immunosorbent Assay (veterinary) |
4 | Dog Diseases (epidemiology) |
4 | Disease Notification (statistics & numerical data) |
4 | Diphtheria-Tetanus-Pertussis Vaccine (administration & dosage) |
4 | Cross Reactions |
4 | Cross Infection (diagnosis) |
4 | Critical Care |
4 | Complement Fixation Tests |
4 | Community-Acquired Infections (mortality) |
4 | Community-Acquired Infections (drug therapy) |
4 | Communicable Diseases, Emerging (virology) |
4 | Communicable Diseases, Emerging (veterinary) |
4 | Communicable Disease Control (standards) |
4 | Cardiovascular Diseases (mortality) |
4 | Bacterial Vaccines (administration & dosage) |
4 | Bacterial Infections (microbiology) |
4 | Bacteria (isolation & purification) |
4 | Attitude to Health |
4 | Antigens, Viral (genetics) |
4 | Antibodies, Viral (immunology) |
4 | Antibodies, Bacterial (blood) |
4 | Acute Disease (epidemiology) |
3 | Zanamivir (therapeutic use) |
3 | World War I |
3 | Virus Diseases (veterinary) |
3 | Virus Diseases (therapy) |
3 | Virus Diseases (prevention & control) |
3 | Virus Cultivation (methods) |
3 | Viral Proteins (genetics) |
3 | Viral Matrix Proteins (genetics) |
3 | Viral Load |
3 | Vaccines, Inactivated (adverse effects) |
3 | Vaccines, Inactivated (administration & dosage) |
3 | Vaccines, Combined (immunology) |
3 | Vaccines, Attenuated (standards) |
3 | Vaccination (ethics) |
3 | Travel (statistics & numerical data) |
3 | Tetanus (prevention & control) |
3 | Tertiary Care Centers |
3 | Swine Diseases (transmission) |
3 | Sweden (epidemiology) |
3 | Spain (epidemiology) |
3 | Societies |
3 | Serotyping |
3 | Sequence Homology |
3 | Self Report |
3 | Rotavirus Vaccines (administration & dosage) |
3 | Risk Assessment (statistics & numerical data) |
3 | Respiratory Tract Infections (therapy) |
3 | Respiratory Tract Infections (microbiology) |
3 | Respiratory Tract Diseases (mortality) |
3 | Respiratory Syncytial Viruses (isolation & purification) |
3 | Respiratory Syncytial Virus, Human (isolation & purification) |
3 | Respiratory Syncytial Virus Infections (diagnosis) |
3 | Respiration, Artificial |
3 | Residence Characteristics |
3 | Regression Analysis |
3 | Reference Standards |
3 | Reassortant Viruses (isolation & purification) |
3 | Reassortant Viruses (classification) |
3 | Randomized Controlled Trials as Topic |
3 | Quality Control |
3 | Public Health Administration |
3 | Product Surveillance, Postmarketing |
3 | Pregnancy Complications, Infectious (prevention & control) |
3 | Pregnancy Complications, Infectious (epidemiology) |
3 | Practice Patterns, Physicians' (statistics & numerical data) |
3 | Poliovirus Vaccine, Inactivated (immunology) |
3 | Poliovirus Vaccine, Inactivated (administration & dosage) |
3 | Pneumonia, Viral (epidemiology) |
3 | Pneumonia, Viral (drug therapy) |
3 | Pneumonia, Bacterial (mortality) |
3 | Pneumonia, Bacterial (epidemiology) |
3 | Pneumococcal Vaccines (immunology) |
3 | Picornaviridae Infections (epidemiology) |
3 | Pertussis Vaccine (administration & dosage) |
3 | Patient Selection |
3 | Patient Participation (statistics & numerical data) |
3 | Patient Isolation |
3 | Particulate Matter (analysis) |
3 | Paramyxoviridae Infections (virology) |
3 | Papillomavirus Vaccines (administration & dosage) |
3 | Orthomyxoviridae Infections (transmission) |
3 | Orthomyxoviridae Infections (prevention & control) |
3 | Orthomyxoviridae (growth & development) |
3 | Orthomyxoviridae (genetics) |
3 | Occupational Exposure |
3 | Nursing Staff, Hospital (statistics & numerical data) |
3 | Newcastle disease virus (isolation & purification) |
3 | Newcastle Disease (epidemiology) |
3 | Neutralization Tests |
3 | Neuraminidase (immunology) |
3 | Neuraminidase (chemistry) |
3 | Nasopharynx (microbiology) |
3 | Narcolepsy (epidemiology) |
3 | Mutation, Missense |
3 | Multivariate Analysis |
3 | Multiple Sclerosis (immunology) |
3 | Multiple Sclerosis (epidemiology) |
3 | Motivation |
3 | Mortality |
3 | Molecular Epidemiology |
3 | Molecular Diagnostic Techniques (methods) |
3 | Models, Organizational |
3 | Models, Economic |
3 | Models, Econometric |
3 | Mexico |
3 | Metapneumovirus (isolation & purification) |
3 | Medical Staff, Hospital (psychology) |
3 | Meat (virology) |
3 | Mandatory Reporting |
3 | Lung (pathology) |
3 | Length of Stay |
3 | Intensive Care Units |
3 | Information Dissemination (methods) |
3 | Influenza in Birds (mortality) |
3 | Influenza A Virus, H7N7 Subtype (pathogenicity) |
3 | Influenza A Virus, H5N8 Subtype (pathogenicity) |
3 | Influenza A Virus, H5N1 Subtype (immunology) |
3 | Influenza A Virus, H1N2 Subtype (genetics) |
3 | Influenza A Virus, H1N2 Subtype (classification) |
3 | Infection Control |
3 | Immunosuppressive Agents (therapeutic use) |
3 | Immunization |
3 | Immunization Programs (organization & administration) |
3 | Immunization (adverse effects) |
3 | Immune Sera |
3 | Humidity |
3 | History, 19th Century |
3 | Hepatitis B Vaccines (administration & dosage) |
3 | Hemagglutinins, Viral (genetics) |
3 | Hemagglutinins (genetics) |
3 | Hemagglutinin Glycoproteins, Influenza Virus (chemistry) |
3 | Health Services Needs and Demand (trends) |
3 | Health Promotion |
3 | Health Planning Guidelines |
3 | Health Personnel (psychology) |